Fiscal Year: January - December
Danaher Corporation (DHR), listed on the NYSE, has a market capitalization of $121.74B. As of May 22, 2026, the stock is trading at $172.00 per share@else an unavailable price , offering investors a clear view of its current market value. Danaher Corporation is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 33.6, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Danaher Corporation also offers a dividend yield of 0.93%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Danaher Corporation (DHR) may be overvalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Danaher Corporation is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Danaher Corporation, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Danaher Corporation is 23.06, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Danaher Corporation (DHR) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Danaher Corporation (DHR) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be overvalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Danaher Corporation (DHR) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Danaher Corporation. To access the full SS Score, consider upgrading your subscription.
Danaher Corporation is a significant player in the industry sector, with a market capitalization of $121.74B and a competitive P/E ratio of 33.6. Investors should compare these metrics with industry peers to gauge whether Danaher Corporation is outperforming or underperforming within its sector.
RBC Capital resumed coverage of Danaher (DHR) with an Outperform rating and $200 price target The firm sees the company’s growth recovering with the bioprocess market improving. A sustained bioprocess...
WASHINGTON, May 6, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Heal...
WASHINGTON, May 5, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stoc...
Masimo (MASI) announced that its stockholders voted in favor of the proposal to adopt the previously announced Agreement and Plan of Merger, dated February 16, 2026, by and among Masimo,…
IRVINE, Calif.--(BUSINESS WIRE)--Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to...
Agilent Technologies (A) announced the appointment of Michael Buckner as chief legal officer. Buckner joins Agilent from Danaher Corp. (DHR), where he served as vice president, deputy general counsel,...
Danaher reached a $172.5 million settlement with shareholders who accused the diagnostics and life-sciences company of defrauding them by overstating demand for its equipment as the worst of the COV...
WASHINGTON, April 22, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today that it has priced an offering of the following euro-denominated senior notes (the "Offering"): €...
UBS lowered the firm’s price target on Danaher (DHR) to $250 from $270 and keeps a Buy rating on the shares. The firm still sees potential upside despite respiratory headwinds,…
Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Danaher (DHR) to $245 from $249 and keeps an Outperform rating on the shares. The firm updated its model…
Guggenheim analyst Subbu Nambi lowered the firm’s price target on Danaher (DHR) to $235 from $275 and keeps a Buy rating on the shares. Q1 results were about as the…
Jefferies analyst Tycho Peterson raised the firm’s price target on Danaher (DHR) to $245 from $240 and keeps a Buy rating on the shares after a “solid” Q1 report. Headwinds…
Danaher boosted the upper end of its full-year earnings guidance, following a first-quarter beat fueled by double-digit momentum in its Biotechnology and Life Sciences segments.
Life sciences firm Danaher topped first-quarter profit expectations on Tuesday, fueled by strong demand for its bioprocessing tools used in drug manufacturing, lifting shares 2% in premarket trading.
Today, several major companies are expected to report earnings: 3M (MMM), Annaly Capital (NLY), Danaher (DHR), GE Aerospace (GE), Halliburton (HAL), Intuitive Surgical (ISRG), Northrop Grumman (NOC), ...
Reports Q1 revenue $6B, consensus $6B. Rainer Blair, President and CEO, stated, “Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and…
For the second quarter 2026, the Company anticipates that non-GAAP core revenue will increase in the low-single digit percent range year-over-year.
Consensus $8.40. For full year 2026, the Company continues to expect that non-GAAP core revenue will increase in the 3% to 6% range year-over-year, consensus $25.62B. The Company is also…
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2026 | 5.66B | Analyst x7 | |
| 2027 | 6.13B | 8.35% | Analyst x7 |
| 2028 | 6.89B | 12.28% | Analyst x4 |
| 2029 | 7.51B | 9.06% | Analyst x4 |
| 2030 | 8.05B | 7.16% | Analyst x1 |
| 2031 | 8.38B | 4.14% | Est @4.1% |
| 2032 | 8.69B | 3.69% | Est @3.7% |
| 2033 | 8.99B | 3.38% | Est @3.4% |
| 2034 | 9.25B | 2.95% | Est @3.0% |
| 2035 | 9.51B | 2.81% | Est @2.8% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 5.30B | 1.00 | 5.30B |
| 2025A | 5.26B | 1.00 | 5.26B |
| 2026E | 5.66B | 1.08 | 5.22B |
| 2027E | 6.13B | 1.18 | 5.22B |
| 2028E | 6.89B | 1.27 | 5.41B |
| 2029E | 7.51B | 1.38 | 5.44B |
| 2030E | 8.05B | 1.50 | 5.38B |
| 2031E | 8.38B | 1.62 | 5.16B |
| 2032E | 8.69B | 1.76 | 4.94B |
| 2033E | 8.99B | 1.91 | 4.71B |
| 2034E | 9.25B | 2.07 | 4.47B |
| 2035E | 9.51B | 2.24 | 4.24B |
| Terminal | 164.94B | 2.24 | 73.55B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.
